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Background: Despite great improvement in the surgical treatment and adjunctive therapy for oral squamous cell
carcinoma (OSCC), prognosis remains dismal in advanced cases. Regional metastatic disease is known to reduce
recurrence free survival and disease specific survival significantly. The present study was conducted to evaluate the
role of cell adhesion molecules β-catenin, E-cadherin and vimentin in predicting tumour metastasis of OSCC.
Methods: A total of sixty cases of oral squamous cell carcinoma were included for the study which comprised of
30 cases with lymph node metastases and 30 cases without metastases. Immunohistochemistry was performed for
β-catenin, E-cadherin and vimentin on both the test groups along with 30 controls from normal buccal mucosa
and inflammatory lesions each.
Results: There was no significant difference between the immunoreactivity for β-catenin, E-cadherin and vimentin
between OSCC with and without lymph node metastases. Vimentin immunopositivity was noted with varying
intensity in all cases of OSCC.
Conclusions: E-cadherin and β-catenin are probably not the key determinants for regional metastases in OSCC.
The role of vimentin expression in OSCC and metastases is controversial and needs to be studied further.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/6506095201182002.
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Oral squamous cell carcinoma (OSCC) is the sixth most
common malignancy in the world and ranks as first in
males in the Indian subcontinent. It is a major cause of
cancer morbidity and mortality [1]. Despite great im-
provement in surgical treatment and adjunctive therapy,
prognosis remains dismal in advanced cases. Regional
metastatic disease is known to reduce recurrence free
survival and disease specific survival significantly [2].
Adhesion molecules play a central role in pathogenesis
and progression of malignant tumours [3]. Vimentin is an
intermediate filament found predominantly in mesenchy-
mal cells, but not in epithelial cells. However, it also exists* Correspondence: mks@aiims.net.in
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article, unless otherwise stated.in some carcinoma cell lines [4-6] and squamous cell
carcinomas [7,8].
Therefore, it is important to evaluate the role of cell
adhesion molecules like β-catenin and E-cadherin along
with vimentin in tumour metastasis of OSCC. In this
study, we studied the immunohistochemical expression
of vimentin, β-catenin and E-cadherin in oral squamous
cell carcinoma with and without lymph node metastasis.Methods
Patients and tissue specimens
A total of 60 cases of primary OSCC diagnosed over a
period of 2 years (2010–2012) in the Department of
Pathology, All India Institute of Medical Sciences were
included for the study. All the patients had been surgically
treated with tumour resection and radical neck dissection.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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therapy (chemotherapy or radiotherapy) before the resec-
tion. Thirty cases with a clinical suspicion of malignancy
but diagnosed as inflammatory lesions on histology and
30 histologically confirmed normal mucosal margins from
the resection specimens were included as control group.
This study was approved by the Ethics Committee of All
India Institute of Medical Sciences.
Histopathological evaluation
Specimens from all the cases were fixed in 10% formal-
dehyde solution and embedded in paraffin. Histological
diagnosis was made on haematoxylin and eosin stained
sections according to the revised criteria given by the
World Health Organization (2005). OSCCs were classified
into well, moderately and poorly differentiated grades.
Staging was done based on TNM staging into four cat-
egories, stage I-IV.
Immunohistochemistry
Tissue sections (4 μm) cut from representative paraffin
blocks were deparaffinised in xylene and rehydrated
through graded alcohols. Endogenous peroxidase was
blocked using 4% hydrogen peroxide. For antigen retrieval,
the sections were processed by conventional microwave
heating in 10mMol/L sodium citrate retrieval buffer
(pH 6.0) for 30 minutes. The sections were then incubated
for overnight with primary antibody at 4°C in a humid
chamber for β catenin (Spring bioscience), E-cadherin
(Spring bioscience) and vimentin (Thermo scientific). The
dilutions used for the primary antibodies were 1:250,
1:100 and 1:400 for β catenin, E-cadherin and vimentin
respectively. The sections were subsequently incubated
with anti-mouse immunoglobulin in phosphate buff-
ered saline (PBS) containing carrier protein and 15 mM
Sodium Azide (large volume universal DAKO LSAB kit,
Peroxidase, M/s Dakopatts, Denmark) at room temperature
for 30 minutes for β-catenin, E-cadherin and vimentin. The
sections were then washed three times with PBS (pH 7.2)
for 2 min. The reaction product was developed with 3, 30-
diaminobenzidine and counterstained with haematoxylin.
Immunoreactivity in the tissue was judged independ-
ently by two pathologists who were blinded to the clinical
data and other immunohistochemical results. Normal oral
mucosal tissues were used as positive control. Negative
controls were included in each slide run with omission of
primary and secondary antibodies.
Evaluation of immunoreactivity
Immunoreactivity was semi quantitatively evaluated on
the basis of staining intensity and distribution using the
immunoreactive score [9,10].
Immunoreactive score = intensity score x proportion
score. The intensity score was defined as 0: negative; 1:weak; 2: moderate; or 3: strong, and the proportion score
was defined as 0: negative; 1: <10%; 2: 10-50%; 3: >50-80%;
or 4: >80% positive cells. The total score ranged from 0 to
12. Immunoreactivity was divided into three groups based
on the final score: negative immunoreactivity was defined
as a total score of 0, low immunoreactivity was defined as
a total score of 1–4, and high immunoreactivity was
defined as a total score >4.
Statistical analysis
The correlation between clinicopathological parameters
and β catenin, E-cadherin and vimentin expression were
analysed using the chi square test and Fisher’s exact test.
A p value <0.05 was considered statistically significant.
Results
Clinicopathological characteristics
A total of 60 cases of OSCC were analyzed, of which 30
cases had lymph node metastasis. Majority of them were
males (77%) and females constituted 14 (23%) cases. Age
range was 23 years to 72 years with a mean age of
44.79 years. Tongue was the most common site involved
(52%). Well differentiated, moderately differentiated and
poorly differentiated squamous cell carcinomas included
38, 20 and 2 cases respectively. Of 60 cases, 21(35%)
cases were Stage III, 17(28%) Stage IV, 16(27%) Stage I
and 6(10%) in Stage II.
Immunohistochemical analysis
Both the control groups revealed a strong membranous
staining pattern of E-cadherin with an absence or reduced
expression in the superficial layer of mature well differen-
tiated cells. Strong membranous β-catenin expression was
observed in the suprabasal to the basal layers with
absence of staining in the superficial layer in both the
control groups. Vimentin expression was detected in the
cytoplasm of the connective tissue mesenchymal cells
of normal oral mucosal tissue, but not in the squamous
epithelium (Figures 1 and 2).
Expression of β-catenin, E-cadherin and vimentin in
OSCC patients
Comparison of expression of β-catenin, E-cadherin and
vimentin in OSCC with and without lymph node metas-
tases is enumerated in Table 1. OSCCs showed a weaker
expression of both β-catenin and E-cadherin than the
control groups (p <0.05). However, there was no signifi-
cant difference in the degree of β-catenin (p = 1.000) and
E-cadherin (p = 0.771) expression in study groups of OSCC
with and without lymph node metastases. Vimentin
expression was seen in all cases of OSCC. Vimentin
was expressed in the cytoplasm of the tumour cells
with weak to moderate intensity. However, there was no
Figure 1 Staining pattern of normal buccal mucosa. A. Normal buccal mucosa, H&E X200; B. High immunoreactivity of β-catenin in normal
buccal mucosa X200; C. High immunoreactivity of E-cadherin in normal buccal mucosa X200; D. Absence of immunostaining for vimentin in
normal squamous epithelium of buccal mucosa X200.
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expression in both the study groups (Figure 3).
Patients without lymph node metastases were nearly
equally distributed in age groups of ≤50 years and >50 years
where as patients with lymph node metastases predom-
inantly belonged to the ≤50 years group. There were no
statistically significant differences between the clinicalFigure 2 Staining pattern of oral lichen planus. A. Oral lichen planus, H&E
of a case of lichen planus X200; C. High immunoreactivity for E-cadherin
of immunostaining for vimentin in squamous epithelium in a case of lichvariables (age, sex, site, size of tumour and histological
differentiation) in OSCC with and without lymph node
metastases as enumerated in Table 2.
There was no statistically significant difference between
the expressions of β-catenin, E-cadherin or vimentin and
clinicopathological variables (age, sex, site, size of tumour,
histological differentiation and stage) in OSCCs with andXX200; B. High immunoreactivity for β-catenin in squamous epithelium
in squamous epithelium of a case of lichen planus X200; D. Absence
en planus X200.
Table 1 Comparison of OSCC with and without lymph node metastases
Groups Beta catenin p value E- cadherin p value Vimentin p value
≤4 5–12 ≤4 5–12 ≤4 5–12
OSCC without lymph node metastasis (n = 30) 9 21 0.771 7 23 1.000 25 5 0.360
OSCC with lymph node metastases (n = 30) 7 23 6 24 21 9
Balasundaram et al. Diagnostic Pathology 2014, 9:145 Page 4 of 7
http://www.diagnosticpathology.org/content/9/1/145without lymph node metastases as listed in Table 3. Thus,
all these variables did not affect the expression of adhesion
molecules.
Discussion
Oda T et al. proposed three mechanisms of alteration
of cadherin-mediated cell adhesion system in human
cancers in vivo and in vitro. The first is down-regulation
of E-cadherin expression and its gene mutation [11]. Exist-
ence of altered E-cadherin expression in human cancers
and a significant relationship between reduced E-cadherin
expression and clinicopathological factors, such as dedif-
ferentiation, invasiveness, or metastasis was previously
reported [12]. The second is abnormality or deletion of
catenins [13,14]. The third abnormality is biochemical
modification of catenins. It has been demonstrated that
tyrosine phosphorylation of β-catenin induced by various
factors (eg. v-src, hepatocyte growth factor and epidermal
growth factor) suppresses E-cadherin function in vitro [15].
The present study revealed the down regulation of
molecular markers β-catenin and E-cadherin in OSCC
along with aberrant expression of vimentin. However,
the present study did not show any significant differenceFigure 3 Staining pattern of squamous cell carcinoma. A. Squamous c
β-catenin in a case of squamous cell ]carcinoma X200; C. Low immunoreac
immunoreactivity for vimentin in a case of squamous cell carcinoma X200.in the expression of E- cadherin, β- catenin and vimentin
in OSCC with and without lymph node metastases.
As proposed by various studies [16-19], there was de-
creased expression of E-cadherin and β-catenin in OSCC
tumour cells, in comparison to strong expression in the
control groups. This was statistically significant in OSCC
without lymph node metastasis (p = 0.002, p = 0.011) and
OSCC with lymph node metastases (p = 0.011, p = 0.024).
Epithelial-mesenchymal transition is an important bio-
logical process during development and oncogenesis. It
is characterized by a reduction of epithelial polarities and
production of mesenchymal phenotypes. Down regulation
of epithelial marker like E-cadherin and increase in
mesenchymal marker vimentin are hallmarks of transition
[20,21].
Few studies have detected the expression of vimentin
in OSCC patients and cell lines [22,23]. Similar feature
was noted in the present study.
Down regulation and loss of E-cadherin was associated
with lymph node metastases and advanced stage of OSCC
according to various studies [18,24-26] while few studies
[16,17,27,28] failed to prove this prognostic value. The
present study followed the latter trend.ell carcinoma, buccal mucosa, H&E X200; B. Low immunoreactivity of
tivity of E-cadherin in a case of squamous cell carcinoma X200; D. Low
Table 2 Correlation of clinical variables in OSCC with and










Age: ≤ 50 yrs 16 24
0.054
> 50 yrs 14 6
Sex: Female 6 8
0.761
Male 24 22
Site: Tongue 14 17
0.605
Buccal mucosa 16 13
Size: ≤ 4 cm 24 23
1.000
> 4 cm 6 7
Differentiation: WDSCC 17 21
0.698MDSCC 12 8
PDSCC 1 1
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has been correlated by Rodrigo et al. with the presence
of nodal metastatic disease in a study on 101 patients
with supraglottic laryngeal carcinoma [29] although, few
studies failed to show this relationship [27,30]. Bukholm
et al. [31] reported that there was no significant difference
between the expression of E-cadherin and the presence of
regional metastasis in human breast cancer, and it is said
that the significance of changes in the E-cadherin complex
may vary from tumour to tumour [32].
Reduced β-catenin staining was a predictive marker
for lymph node metastases in OSCC according to few
studies [24,33,34] and not by others [16,27,35]. The
present study did not have a significant difference in theTable 3 Correlation of β catenin, E-cadherin and vimentin exp
Variable Total cases(n = 60) β catenin P value
Low High
Male 46 15 31
0.085
Female 14 1 13
≤ 50 yrs 40 11 29
1.000
> 50 yrs 20 5 15
Tongue 31 8 23
1.000
Buccal mucosa 29 8 21
WDSCC 38 10 28
0.538MDSCC 20 4 16
PDSCC 2 1 1
≤ 4 cm 47 12 35
0.731
> 4 cm 13 4 9
Stage I&II 22 6 16
1.000
Stage III&IV 38 10 28reduced expression of β-catenin and lymph node metas-
tases in OSCC.
Several factors related to methodology may account for
the discrepancy in results. The method of evaluation of
immunostaining and the definition of under-expression is
quite variable, hence compromising accurate comparison
of data.
In some studies, a semi-quantitative estimation of
the immunoreactive intensity was used [24,25,33,36,37]
with varying percentage criteria, while other studies have
not assessed expression according to the percentage of
positively stained cells [38,39]. Moreover, the expression
analysis has been carried out in different areas of the
tumour by different investigators. Some studies have
focussed on the invasive tumour front [33,38] while
other studies have examined expression in random areas
[24,36,37,39] within the tumour. It would, however, appear
from the results in the present study and other studies
on OSCC [16,17,25,27,28,35,36,39] that E-cadherin and β-
catenin are probably not the key determinants for regional
metastases in OSCC.
In this study, all tumors in both the groups expressed
cytoplasmic positivity for vimentin with varying inten-
sity. Of 60 cases of OSCC, 45 cases (75%) exhibited a
low immunoreactive score and 15 cases (25%) exhibited
high immunoreactive score. Poorly differentiated OSCC
constituted two cases, of which one exhibited high im-
munoreactive score (50%). The number of cases in the
poorly differentiated carcinoma category was less for a
valid comparison.
Various molecules have been studied in head and neck
carcinomas. Low level of p27 expression has been reported
an unfavorable prognostic factor for patients with nasopha-
ryngeal carcinoma [40]. CypA/MMP9 signal pathway andression level of tumours and clinical variables
E-cadherin P value Vimentin P value
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transformation of esophageal squamous cell carcinoma
(ESCC) [41,42]. Also, over-expression of ABCG2 and
V-ATPase is noted in ESCC. RNAi targeting CXCR4 is
known to inhibit proliferation and invasion of esophageal
carcinoma cells [43]. Both ABCG2 and V-ATPase are
over-expressed in esophageal squamous cancer cells
[44]. Some new molecules are being studied in head
and neck squamous cell carcinomas (HNSCC). Mir-205
has been demonstrated as a novel molecular marker for
the detection of metastatic HNSCC [45]. In another study,
primary tumors and positive nodes of the metastatic cases
revealed decreased expression of collagen XVIII and
CBP2/HSP47 in metastases [46]. More studies on role
of integrins, epidermal growth factor receptor, matrix
metalloproteinases, cathepsins, chemokine receptors and
angiogenesis markers are needed for future.
Conclusions
Expression of β-catenin and E-cadherin is though down-
regulated in oral squamous cell carcinomas, it solely does
not predicts lymph node metastasis. Aberrant vimentin
expression is seen in these tumours. Loss of intercellular ad-
hesion is only one of the stages required for the occurrence
of metastases; there could be a need for other phenomena,
such as loss of cell adhesion to the extracellular matrix,
which can be caused by the metalloproteinases expression,
which has to be further evaluated. Detailed studies on
KCl co transporter −3 (KCC 3) functions with emphasis on
disruption of E-cadherin/β–catenin complex formation and
cell-cell junction dysfunction are required.
Abbreviation
OSCC: Oral squamous cell carcinoma.
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